Spectrum To Complete Levofolinic Acid NDA In Q1 2007 Following Acquisition
This article was originally published in Pharmaceutical Approvals Monthly
Spectrum hopes to launch the active isomer form of leucovorin, levofolinic acid, in late 2007 following acquisition of the compound from private firm Targent, announced March 20
You may also be interested in...
Adventrx' Phase III trial of CoFactor will evaluate the folate-based biomodulator's ability to improve the efficacy and safety of the chemotherapeutic agent 5-fluorouracil in patients with metastatic colorectal cancer
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class